Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who ...
Nature3y
Trials of first-in-class bioartificial liver indicate potential
Data from the Asian Pacific Association for the Study of the Liver (APASL) showed 28-day mortality rates of 41.9% and 90-day mortality rates of 56.1%. Mortality rates from the European Association ...
Nasdaq1mon
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
This was observed rapidly and maintained over the period of the study ... rare cholestatic liver disease portfolio. Kayfanda is known in ALGS as Bylvay® outside of the European Union (E.U ...